ClinicalTrials.gg
RecruitingNCT05029336Updated Nov 16, 2026

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

A Phase 2 interventional study of Depletion of CD3/CD19 in an autologous stem cell transplant in Systemic Lupus Erythematosus and Systemic Sclerosis, sponsored by Stephan Grupp MD PhD. Recruiting at 1 site in United States. Open to participants aged 8 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Stephan Grupp MD PhD · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Start date movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
8 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Planned enrollment
317th of 407
20 · median 70
Started
2026
with 28 others
Phase 2
120 of 477
10 open now
Primary completion
2027-12
later than 54 of 125 live
Registered
332nd of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 317th largest by planned enrollment of the 407 interventional ones that give a count, is one of 29 that started in 2026, is one of 120 in phase 2, reaches primary completion later than 54 of the 125 other live ones, and was the 332nd registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

81 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 8 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy. This study proposes a pilot study to evaluate this therapeutic strategy in children and young adults with systemic sclerosis (SSc) and systemic lupus erythematosis (SLE), two potentially life threatening autoimmune diseases that may response to this therapeutic approach.

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Systemic Sclerosis
04

Who can participate

Ages eligible
8 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 8 ≤ 25 years at time of enrollment.
  2. Severe systemic sclerosis or systemic lupus erythematosus based on specific criteria
  3. Adequate organ function status
  4. No active, untreated infections.

Exclusion criteria

Exclusion Criteria:

  1. Previous hematopoietic stem cell transplant () or solid organ transplant
  2. Pregnancy
  3. Ongoing participation in a clinical trial testing an drug or ongoing receipt of disallowed disease modifying anti-rheumatic drugs (DMARD)
  4. Severe comorbidity that jeopardizes the ability of the subject to tolerate therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CD3/CD19 depleted ASCT

    The test article is autologous stem cell transplant with a CD3/CD19-depleted stem cell product.

    Biological: Depletion of CD3/CD19 in an autologous stem cell transplant

Interventions

  • BiologicalDepletion of CD3/CD19 in an autologous stem cell transplant

    The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.

    Also known as: CD3/CD19 depletion using cliniMACs device

06

What researchers measure

Primary outcomes

  1. Two-year progression free survival

    Survival without evidence of relapse or disease progression

    Time frame: 2 years

Secondary outcomes

  1. Disease-specific response/progression endpoints: SSc cohort

    o Pulmonary function: Change in forced vital capacity (FVC), total lung capacity (TLC) or diffusing capacity of the lung for carbon monoxide (DLCO) \> 10%

    Time frame: 24 months following transplant

  2. Disease-specific response/progression endpoints: SSc cohort

    o Skin condition: An improvement is indicated by a decrease on modified Rodan Skin Score (mRSS) of \> 5 points

    Time frame: 24 months following transplant

  3. Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort

    o Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) \< 4

    Time frame: 24 months following transplant

  4. Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort

    o Complete remission off therapy (BILAG D/E only or SLEDAI=0 and no SLE treatment except hydroxychloroquine)

    Time frame: 24 months following transplant

  5. Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort

    o Serologic response: presence of positive ANA, anti-dsDNA and anticardiolpin antibody titers

    Time frame: 24 months following transplant

  6. Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort

    o Serologic response: abnormal complement C3 and C4 levels

    Time frame: 24 months following transplant

  7. Overall survival (OS)

    Overall survival will be considered as time from transplant to death from any cause

    Time frame: 2 and 5 years following transplant

  8. Event free survival (EFS)

    Events include death, and significant persistent organ damage o An event based on organ dysfunction must be documented on at least two occasions, at least three months apart and include: respiratory failure (resting O2 saturation \< 88%), renal failure (chronic dialysis) and cardiomyopathy (clinical congestive heart failure New York Class III or IV, left ventricular ejection fraction (LVEF) \< 30% by echocardiogram despite therapy)

    Time frame: 2 and 5 years following transplant

  9. 100 day treatment-related mortality

    Defined as death from non-disease related causes in the 100 days from stem cell infusion

    Time frame: 100 days from stem cell infusion

  10. Time to engraftment

    • Achieving an absolute neutrophil count (ANC) \> 500 cells/uL and an unsupported platelet count of \> 20,000 cells/uL for three consecutive days

    Time frame: 3 days

  11. Change in quality of life

    * Quality of life will be measured based on the Patient-Reported Outcomes measurement Information System (PROMIS) that evaluates physical, mental and social health in adults and children. * patient reported outcome measurement information system (PROMIS) will be administered to each patient (or proxy) prior to autologous stem cell transplant (ASCT) and three times/year for the first two years post-transplant and then annually until five years post-transplant.

    Time frame: prior to autologous stem cell transplant (ASCT) until 5 years post-transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 95 phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 55. This study's planned 13 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 31, 2021
StartEst.
Nov 2026was Mar 2026
Primary completionEst.
Dec 2027
CompletionEst.
May 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 2026→Nov 2026
Nov 16, 2026
Contact
Study contact changed: H•••@chop.edu · •••5168→c•••@chop.edu · •••5168. See the current contact
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Mar 2026→Nov 2026
    Contact Study contact changed: H•••@chop.edu · •••5168→c•••@chop.edu · •••5168. See the current contact
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05029336
Lead sponsor
Stephan Grupp MD PhD
Responsible party
Stephan Grupp MD PhD (Director of Cancer Immunotherapy Program, Children's Hospital of Philadelphia) — Sponsor-investigator
First posted
Aug 31, 2021
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
May 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Kellie Patterson, BSN, RN
Contact
cttsbmtintake@chop.edu
(215) 590-5168
Caitlin Elgarten, MD
Contact
elgartenc@chop.edu
2158079038
Caitlin Elgarten, MD
principal investigator · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion